Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44676 | 0.92 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30752070 | 0.92 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29598813 | 0.91 | FABP5 (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7767154 | 0.91 | FABP5 (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL393445 | 0.90 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30396315 | 0.90 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8612414 | 0.90 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7720044 | 0.87 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL34469817 | 0.87 | FABP5 (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30807400 | 0.87 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106716237-B | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element | 日产化学工业株式会社 | 2020-09-25 | — | — | CN | disclosed |
| EP-2797879-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| US-9872847-B2 | Phenyl carbamate compounds for use in preventing or treating a movement disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-01-23 | — | — | US | disclosed |
| EP-2797878-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-08-16 | — | — | EP | disclosed |
| EP-2797880-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-03-01 | — | — | EP | disclosed |
| US-20160024000-A1 | Phenyl Carbamate Compounds for Use in Preventing or Treating a Movement Disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| EP-2968212-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968210-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968213-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING A MOVEMENT DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2797879-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014142520-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014142477-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014142518-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING A MOVEMENT DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275243-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013100568-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013100569-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING MULTIPLE SCLEROSIS | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013100570-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013100567-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165408-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165409-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165408-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY | CHAT, BCHE, GABBR1 | KMT2A 549/4885FABP5 2273/4885FABP7 369/4885 |
| US-20130165409-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN | ACHE, HDAC3, TRPV1 | KMT2A 687/4885FABP5 1581/4885FABP7 1121/4885 |
| US-20140275243-A1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY AND EPILESY-RELATED SYNDROMES | CACNA1A, KDM1A, KDM3A | KMT2A 171/4885FABP5 1599/4885FABP7 719/4885 |
| US-20160024000-A1 | Phenyl Carbamate Compounds for Use in Preventing or Treating a Movement Disorder | COMT, CHAT, ACHE | KMT2A 404/4885FABP5 1180/4885FABP7 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.